<DOC>
	<DOC>NCT00391274</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior chemotherapy.</brief_summary>
	<brief_title>Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic or cytologic diagnosis NSCLC (Stage IIIA, IIIB, or IV), not amenable to curative surgery or radiotherapy At least one prior chemotherapy for palliative therapy Response Evaluation Criteria In Solid Tumors (RECIST) criteria for disease status assessment Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Concurrent administration of any other tumor therapy Pregnant or breast feeding Serious concomitant disorders Inability or unwillingness to take folic acid or vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>